证券代码： 300434 证券简称：金石东方 编号：2017-01 四川金石东方新材料设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 保宁资本 黄静 | | | 人员姓名 | | | | 时间 | 2017 年 6 月 30 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | 副总经理、董秘：林 强 | | | 员姓名 | 证券事务代表： 张天涯 | | | 投资者关系活动 主要内容介绍 | 一、基本情况介绍 | | | | | 公司的主营业务为 ...

证券代码:300434 证券简称:金石东方 资者关系活动记录表 四川金石东方新材料设备股份有限公司 | --- | --- | --- | --- | |----------------|------------------------------------|------------------------------------------|--------| | | 团特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | 口其他 (请文字说明其他活动内容) | | | | | 天府新区对冲基金学会 | | 李辉 | | | 天府新区对冲基金学会 | | 曹多荣 | | | 天府新区对冲基金学会 | | 刘小华 | | | 天府新区对冲基金学会 | | 杨杰鑫 | | | 天府新区对冲基金学会 | | 王钰婷 | | | 浙商证券股份有限公司天府营业部 | | 萄国平 | | | 浙商证券股份有限公司天府营业部 | | 陈玉莎 | | | 成都金枫银帆投资管理有限公司 ...

证券代码：300434 证券简称：金石东方 编号：2019-01 四川金石东方新材料设备股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------|----------------------------------|--------| | | 特定对象调研 □分析师会议 | | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 天府新区对冲基金学会 | | 李辉 | | 人员姓名 | 天府新区对冲基金学会 | | 曹多荣 | | | 天府新区对冲基金学会 | | 刘小华 | | | 天府新区对冲基金学会 | | 杨杰鑫 | | | 天府新区对冲基金学会 | | 王钰婷 | | | 浙商证券股份有限公司天府营业部 | | 苟国平 | | | 浙商证券股份有限公司天府营业部 | | 陈玉莎 | | | ...

Financial Performance - The company achieved a revenue of 711 million CNY in the first three quarters of 2022, remaining stable year-on-year [1] - Net profit reached 107 million CNY, representing a year-on-year increase of 32.20% [1] - The net profit from regular operations was 85 million CNY, with a net cash flow from operating activities of 122 million CNY, reflecting a growth of 16.64% [2] Product Performance - The main products in the pharmaceutical sector, "Kuaike" and "Xiaokuaike," accounted for 54%, 43%, and 50% of total revenue from 2019 to 2021, respectively [2] - In 2021, "Kuaike" contributed 36% and "Xiaokuaike" contributed 15% to the total revenue [2] - The company has over 70 products in its portfolio, including prescription drugs, OTC products, and health foods [3] Market Dynamics - The demand for cold medicine decreased due to the widespread use of masks during the COVID-19 pandemic [3] - The company is focusing on expanding its sales network, particularly in second and third-tier cities, while consolidating its strengths in key markets [3] - The sales of "Kuaike" and "Xiaokuaike" are recovering following the relaxation of restrictions on cold medicine sales in the second half of the year [4] Strategic Initiatives - The company is exploring new product development through self-research, partnerships, and licensing agreements [3] - It has made significant investments in the new materials and machinery sector, focusing on advanced technologies such as steel-reinforced plastic composite pipes and vacuum coating equipment [4][5] - The vertical circulation parking system project is a key development area, addressing the growing demand for parking solutions in urban areas [5]

编号：2022-001 证券代码： 300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | √ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | | | | 参与单位名称及 | □ 其他 投资者网上提问 | （请文字说明其他活动内容） | | 人员姓名 | | | | | | | | 时间 地点 | 2022 年 5 月 27 日 ( | 周五 ) 下午 15:00~17:00 ...

证券代码：300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |--------------|--------------------------------------|----------------------| | | □ 特定对象调研 □ | 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活 | □ 新闻发布会 □ | 路演活动 | | 动类别 | □ 现场参观 | | | | √ 其他 （ 2022 | 年半年度业绩交流会） | | | 深圳普赞普基金 张超雨 | | | | 西藏合众易晟投资 | | | | 兴银基金 方军平 | | | | 华安证券 江卉 | | | | 福建鑫诺嘉誉投资 | | | | 东北证券 赵朝旋 | | | | 华安证券 谭国超 | | | 参与单位名称 | 上海和谐汇一资产 | | | 及人员姓名 | 上海恒穗资产 骆华森 | | | | 铭箭投资 张健 | | | | 东北证券 刘宇腾 | | | | 上海重阳投资 胡敏 | | | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥232,007,882.58, representing an increase of 18.13% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 reached ¥24,808,867.41, a significant increase of 264.15% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥22,051,954.33, up 281.74% from the previous year[4] - The company's basic earnings per share for Q3 2022 was ¥0.06, reflecting a 200.00% increase compared to the same period last year[4] - Total operating revenue for the period was CNY 711,438,394.76, a decrease of 2.4% from CNY 731,928,047.69 in the previous period[15] - Net profit attributable to shareholders of the parent company increased to CNY 107,008,293.50, up 32.1% from CNY 80,944,550.26[16] - Basic and diluted earnings per share rose to CNY 0.27, compared to CNY 0.20 in the previous period[16] - The company reported a total profit of CNY 128,909,102.88, up from CNY 99,405,024.07 in the previous period[16] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,668,779,411.06, a decrease of 3.59% from the end of the previous year[4] - The company's total assets as of September 30, 2022, amount to ¥2,668,779,411.06, a decrease from ¥2,768,127,717.25 at the beginning of the year[13] - Current assets decreased from ¥946,786,046.66 to ¥879,865,267.01, reflecting a decline of approximately 7.1%[12] - Total liabilities decreased from ¥606,118,784.35 to ¥474,631,727.43, a reduction of about 21.7%[13] - The total equity attributable to shareholders of the parent company was CNY 2,162,465,481.65, an increase from CNY 2,083,751,254.61[14] Cash Flow - Operating cash flow for the year-to-date period was ¥122,361,316.43, an increase of 16.64% compared to the previous year[7] - Net cash flow from operating activities was CNY 122,361,316.43, an increase of 16.6% from CNY 104,906,427.50[17] - The cash inflow from operating activities totaled CNY 721,000,195.17, compared to CNY 788,888,511.99 in the previous period[17] - The net cash flow from financing activities was -61,863,857.48 CNY, indicating a significant outflow compared to the previous period[18] - The total cash and cash equivalents at the end of the period amounted to 258,146,823.18 CNY, an increase from the beginning balance of 234,721,831.30 CNY[18] - The net increase in cash and cash equivalents for the quarter was 23,424,991.88 CNY, contrasting with a significant decrease of -168,833,764.73 CNY in the previous period[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,486[9] - The largest shareholder, Gao Yaping, holds 25.11% of shares, totaling 100,878,929 shares[9] - The company has a total of 69,822,051 shares under lock-up agreements, primarily due to management restrictions[11] Investment and Expenses - The company reported a significant increase in asset disposal income of ¥17,741,675.29, compared to a loss of ¥1,296.13 in the same period last year[7] - The company’s investment activities generated a net cash flow of -¥38,948,649.08, a decrease of 82.88% compared to the previous year[7] - Research and development expenses increased to CNY 30,020,328.40, up 8.9% from CNY 27,762,817.13[15] Audit and Compliance - The company did not undergo an audit for the third quarter report[19]

证券代码：300434 证券简称：金石亚药 公告编号：2022-032 四川金石亚洲医药股份有限公司 关于参加四川辖区上市公司 2022 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，四川金石亚洲医药股份有限公司（以下 简称"公司"）将参加由四川证监局、四川省上市公司协会与深圳市全景网络有 限公司联合举办的"2022 年四川辖区上市公司投资者集体接待日活动"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2022 年 9 月 16 日（周五）15:00-17:00。 届时公司董事长、总经理魏宝康先生、董事、副总经理、董事会秘书林强先 生、财务总监王庆国先生将在线就公司经营业绩、公司治理、发展战略、经营状 况、融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通 与交流，欢迎广大投资者踊跃参与！ 特此公告。 四川金 ...

Product Structure and Revenue - The company reported a significant concentration in its product structure, with the sales revenue from the "Kuaike" cold medicine series accounting for a high percentage of total revenue and gross profit, indicating a reliance on a few key products[6]. - The sales revenue from the fast cold medicine series accounted for a high percentage of the company's total revenue, indicating a strong market position in this segment[71]. - Key products in the OTC drug segment include "Kuaike" and "Xiaokuaike," which have become well-known brands in China, with significant market advantages[34]. - The company has over 70 main products, including the "Kuaike," "Xiaokuaike," and "Jinxing" series, covering various therapeutic areas[39]. Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥479.43 million, a decrease of 10.48% compared to ¥535.54 million in the same period last year[26]. - Net profit attributable to shareholders increased by 10.88% to approximately ¥82.20 million, up from ¥74.13 million in the previous year[26]. - Basic and diluted earnings per share both rose to ¥0.2046, reflecting a 10.89% increase from ¥0.1845[26]. - The company reported a net loss of CNY 115,378,659.68, compared to a loss of CNY 197,578,085.77 in the previous period, indicating an improvement in financial performance[138]. - The total profit for the first half of 2022 was CNY 102,049,692.01, an increase from CNY 87,734,105.57 in the first half of 2021[144]. Research and Development - The company plans to continue its focus on R&D for new products and technologies, aiming to enhance its market position[26]. - The company is focusing on new product development and regulatory approval processes, with potential risks if new products do not meet market demand[6]. - The company aims to enhance its R&D capabilities through internal talent development and external collaborations with research institutions[34]. - The company is actively developing high-end raw materials, including calcium carbonate, to strengthen its market position in the calcium supplement category[38]. Supply Chain and Production - The company has established a stable supply chain with major suppliers, ensuring that raw material needs are met, although future risks include potential shortages and price increases due to external factors[6]. - The company operates four major production bases covering approximately 400 acres, ensuring stable and efficient production capacity across various dosage forms[44]. - The company currently holds 90 drug production approvals and 3 health food production approvals, indicating a diverse product portfolio[71]. Market Risks and Competition - The company is aware of the risks posed by intensified domestic market competition and potential impacts from changes in government policies regarding drug pricing[5]. - The company faces risks from increasing domestic market competition and potential impacts from foreign pharmaceutical companies due to policy changes[69]. - The ongoing COVID-19 pandemic continues to pose risks to the company's financial performance, depending on the development and control measures of the pandemic[74]. Corporate Governance and Shareholder Structure - The company has a total of 11,058 shareholders at the end of the reporting period[120]. - The largest shareholder, Gao Yaping, holds 25.11% of the ordinary shares, totaling 100,878 shares, with no changes during the reporting period[120]. - The company has implemented restrictions on shares held by executives, with specific release dates based on management regulations[118]. - The report highlights the importance of shareholder engagement and transparency in corporate governance practices[121]. Investment and Financial Management - The company reported an investment loss of ¥5,700,992.19, accounting for -5.59% of total profit, primarily due to bank wealth management products and external investment impacts[52]. - The total investment amount for the reporting period was ¥106,952,336.12, representing a decrease of 43.41% compared to the previous year[57]. - The company has a total of 2,025.72 million in entrusted financial management, with an outstanding balance of 6,909.54 million[63]. Compliance and Internal Controls - The company has implemented strict internal control standards for product quality, exceeding national standards, and has not faced major quality disputes during the reporting period[7]. - There were no significant environmental violations or penalties reported during the reporting period, indicating compliance with environmental regulations[87]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[91]. Future Outlook - The company plans to expand its market presence and invest in new product development in the upcoming quarters[157]. - Future guidance indicates a positive outlook with expected revenue growth driven by new market strategies and product launches[1]. - The management remains optimistic about future performance, despite the current revenue decline, citing strong cash flow and profitability improvements[26].

Financial Performance - The company's revenue for Q1 2022 was ¥314,985,330.83, a decrease of 16.42% compared to ¥376,878,105.52 in the same period last year[3] - Net profit attributable to shareholders was ¥66,575,529.07, down 15.62% from ¥78,903,060.71 year-on-year[3] - The company reported a basic earnings per share of ¥0.17, a decrease of 15.00% from ¥0.20 in the same period last year[3] - Total operating revenue for the current period is CNY 314,985,330.83, a decrease of 16.4% compared to the previous period's CNY 376,878,105.52[20] - Net profit for the current period is CNY 65,601,623.66, a decrease of 16.5% from CNY 78,609,558.98 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 155.25%, reaching ¥15,346,997.87, compared to a negative cash flow of ¥27,776,881.44 in the previous year[3] - Cash and cash equivalents decreased from CNY 235,431,122.99 to CNY 210,215,459.01, a decline of about 10.7%[16] - Total current assets decreased from CNY 946,786,046.66 at the beginning of the year to CNY 821,642,972.78, a reduction of approximately 13.2%[17] - Operating cash flow for the current period is CNY 15,346,997.87, compared to a negative cash flow of CNY -27,776,881.44 in the previous period[25] - Total cash inflow from operating activities is CNY 264,446,558.18, while total cash outflow is CNY 249,099,560.31, resulting in a net cash inflow[25] Equity and Liabilities - Total assets at the end of the reporting period were ¥2,644,934,285.63, down 4.45% from ¥2,768,127,717.25 at the end of the previous year[3] - The company's equity attributable to shareholders increased by 2.18% to ¥2,129,257,386.23 from ¥2,083,751,254.61 at the end of the previous year[3] - Total liabilities decreased from CNY 606,118,784.35 to CNY 455,041,320.47, a reduction of approximately 25%[18] - The company reported a total equity increase from CNY 2,162,008,932.90 to CNY 2,189,892,965.16, an increase of approximately 1.3%[19] Research and Development - The company reported a decrease in research and development expenses to CNY 12,937,760.46 from CNY 21,152,317.65 in the previous period, a reduction of 38.5%[20] - The company received government subsidies amounting to ¥3,035,541.67, primarily related to biopharmaceutical industry research and development[5] Market and Strategic Focus - The decrease in net profit and revenue is attributed to market demand fluctuations and the impact of COVID-19 and industry policies[7] - The company is focusing on enhancing marketing efforts and improving management efficiency while exploring opportunities in traditional Chinese medicine sectors[7] - The company acquired an additional 25% stake in its subsidiary, which contributed to a decrease in minority interests[7] - The company acquired a 25% stake in Zhejiang Di'er Pharmaceutical Co., Ltd. for a transfer price of CNY 35,772,506, increasing its ownership from 52.73% to 77.73%[14] Miscellaneous - The first quarter report of Sichuan Jinshi Asia Pharmaceutical Co., Ltd. is unaudited[26] - The report does not provide specific financial performance metrics or user data for the first quarter[26] - There are no details on future outlook or performance guidance mentioned in the report[26] - The company has not disclosed any new product or technology developments in the first quarter[26] - There is no information regarding market expansion or acquisitions in the report[26] - The report lacks any mention of new strategies implemented during the first quarter[26] - The board of directors has confirmed the absence of an audit for the first quarter report[26] - No specific revenue figures or percentage changes are provided in the report[26] - The report does not include any commentary on competitive positioning or market trends[26] - There are no insights shared regarding operational challenges or achievements in the first quarter[26]